Skip to main content
. 2021 Nov 12;238(4):615–619. doi: 10.1159/000519924

Table 2.

Baseline assessments of the KTC in comparison to patients recruited during the phase 3 study (reSURFACE) at week 28

Assessment KTC
(n = 150)
reSURFACE
(100 mg) (n = 328)
PASI 8.6±4.2 20.5
BSA 11.6±9.1% 34.2%
DLQI 12.0±5.6 14.8
Itch-VAS 5.9±2.6 na

KTC, Kiel Tildra Cohort; na, no data.